RxDoctor Payments Data

Esther Rettig, MD

Ophthalmology · McPherson, KSNPI 1497802722

Payments from drug & device makers

$1,730in general payments, 2019–2025

Across 51 payments — averaging $33.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$330
  • Alcon$312
  • AbbVie$298
  • Sight Sciences, Inc.$201
  • Genentech USA, Inc.$196
  • Sun Pharmaceutical Industries Inc.$145
  • plus $248 from 6 others

What the payments were for

  • Food & beverage$1,67497%
  • Gifts$191%
  • Entertainment$372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,730 in reported general payments places this provider in the 50th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$1,180,654
Medicare patients
859
Services billed
22,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$22,932
CombiganBrimonidine Tartrate/Timolol25$12,009
RhopressaNetarsudil Mesylate25$9,032
RocklatanNetarsudil Mesylat/Latanoprost15$6,180
VyzultaLatanoprostene Bunod14$5,622
Brimonidine Tartrate62$4,530
Travoprost23$3,111
SimbrinzaBrinzolamide/Brimonidine Tart14$2,856
Timolol Maleate392$2,806
Dorzolamide-TimololDorzolamide/Timolol/Pf20$1,873
Latanoprost246$1,706
ValacyclovirValacyclovir Hcl24$1,642
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat66$1,176
Prednisolone Acetate19$1,017
Doxycycline Hyclate43$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$298$34,94159 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$48$15,21240 claims
Bausch & Lomb Americas Inc.Vyzulta$19$5,62214 claims
AlconSimbrinza$312$2,85614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in McPherson

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →